老百姓大药房连锁股份有限公司第五届董事会第十三次会议决议公告

Group 1 - The company held its 13th meeting of the 5th Board of Directors on February 5, 2026, with all 9 directors present [2][4] - The board approved the proposal to permanently supplement working capital with surplus funds from a non-public stock issuance project, totaling 113.08 million yuan [3][13][24] - The surplus funds represent 6.55% of the net amount raised from the 2021 non-public stock issuance, which does not exceed the 10% threshold requiring shareholder approval [13][27] Group 2 - The board also approved the appointment of three new vice presidents: Wang Zhongxin, Chen Lishan, and Feng Shini, effective immediately [5][9] - Wang Zhongxin has extensive experience in the pharmaceutical industry, having held various managerial positions within the company since 2005 [10] - Chen Lishan and Feng Shini continue their roles as the company's financial director and board secretary, respectively [11]